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to-pay threshold.Patients with chronic ulcerative colitis are at increased risk for colorectal neoplasia (CRN).
Surveillance by white-light endoscopy (WLE) or chromoendoscopy may reduce risk of CRN, but
these strategies are underused. Analysis of DNA from stool samples (sDNA) can detect CRN with
high levels of sensitivity, but it is not clear if this approach is cost-effective. We simulated these
strategies for CRN detection to determine which approach is most cost-effective.METHODS: We adapted a previously published Markov model to simulate the clinical course of chronic
ulcerative colitis, the incidence of cancer or dysplasia, and costs and beneﬁts of care with 4
surveillance strategies: (1) analysis of sDNA and diagnostic chromoendoscopy for patients with
positive results, (2) analysis of sDNA with diagnostic WLE for patients with positive results, (3)
chromoendoscopy with targeted collection of biopsies, or (4) WLE with random collection of
biopsies. Costs were based on 2014 Medicare reimbursement. The primary outcome was the
incremental cost-effectiveness ratio (incremental cost/incremental difference in quality-
adjusted life-years) compared with no surveillance and a willingness-to-pay threshold of
$50,000.RESULTS: All strategies fell below the willingness-to-pay threshold at 2-year intervals. Incremental
cost-effectiveness ratios were $16,362 per quality-adjusted life-year for sDNA analysis with
diagnostic chromoendoscopy; $18,643 per quality-adjusted life-year for sDNA analysis with
diagnostic WLE; $23,830 per quality-adjusted life-year for chromoendoscopy alone; and
$27,907 per quality-adjusted life-year for WLE alone. In sensitivity analyses, sDNA analysis with
diagnostic chromoendoscopy was more cost-effective than chromoendoscopy alone, up to a cost
of $1135 per sDNA test. sDNA analysis remained cost-effective at all rates of compliance; when
combined with diagnostic chromoendoscopy, this approach was preferred over chromoendo-
scopy alone, when the speciﬁcity of the sDNA test for CRN was >65%.CONCLUSIONS: Based on a Markov model, surveillance for CRN is cost-effective for patients with chronic ul-
cerative colitis. Analysis of sDNA with chromoendoscopies for patients with positive results was
more cost-effective than chromoendoscopy or WLE alone.Keywords: ICER; QALY; Cost Beneﬁt Analysis; Inﬂammatory Bowel Diseases.Population-level data show an increased incidenceof colorectal cancer (CRC) in inﬂammatory bowel
disease (IBD), speciﬁcally among patients withhip.
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lity-adjusted life-year; sDNA, stool DNA;
hite-light endoscopy; WTP, willingness-extensive, long-standing ulcerative colitis (UC)1 and
Crohn’s disease of the colon.2 Recent data show that
CRC incidence and mortality in patients with UC isMost current article
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Figure 1.Model health state transition diagram from chronic
UC to dysplasia, CRC, surgery, or death. Adapted from
Konijeti GG, Shrime MG, Ananthakrishnan AN, Chan AT.
Cost-effectiveness analysis of chromoendoscopy for colo-
rectal cancer surveillance in patients with ulcerative colitis.
Gastrointest Endosc 2014;79:455–465 and used with
permission.
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endoscopy (WLE).3 Even before this evidence, surveil-
lance colonoscopy became standard of care, based on
several smaller scale case-control and cohort studies,
which in aggregate suggested a beneﬁt from earlier-
stage CRC diagnosis.4 Over the last decade, a growing
body of literature suggests that dye-spray-enhanced
surveillance with chromoendoscopy may be superior
for the detection of dysplastic precursors to CRC.
Although multiple specialty society guidelines endorse
surveillance colonoscopy with WLE,5 the recent SCENIC
consensus statement, jointly issued by the American
Gastroenterology Association and the American Society
for Gastrointestinal Endoscopy, now recommends
chromoendoscopy over standard deﬁnition WLE for
CRC surveillance in patients with US.6
Since its introduction more than a decade ago7 uptake
of chromoendoscopy has been slow, because of the
requirement for additional training, perceived increased
procedure time, and higher costs.8 A recent study
showed that chromoendoscopy might be more
cost-effective than WLE but both modalities seemed to
be above societal willingness-to-pay (WTP) thresholds
when used at currently recommended intervals.9
Complicating matters, patient compliance with CRC sur-
veillance is unacceptably low, even among commercially
insured patients with US.10 Noninvasive testing by stool
DNA (sDNA) is a new potential strategy, hypothesized to
reduce costs and improve surveillance adherence.11–13
Multitarget sDNA has recently been approved by the
United States Food and Drug Administration for average-
risk CRC screening following a pivotal study in which
sensitivity and speciﬁcity of sDNA for CRC were similar
to gold standard WLE.14
The approved multitarget sDNA test, commercialized
as Cologuard (Exact Sciences, Madison WI), assays
mutant KRAS, methylated BMP3, methylated NDRG4, and
a fecal immunochemical test. The fecal immunochemical
test cannot logically be applied in Crohn’s disease and UC
because test speciﬁcity may be compromised by
hemorrhagic inﬂammatory activity. However, recent
case-control data show that stool assay of aberrant DNA
methylation markers achieved >90% sensitivity at 90%
speciﬁcity for CRC in patients with IBD.15,16
Several important questions remain that must be
addressed before sDNA can be used for CRC surveillance
in patients with UC and Crohn’s disease. What sensitivity
and speciﬁcity thresholds should be required of an sDNA
test in this setting? How frequently should the test be
applied? Will sDNA be cost-effective, and if so, at what
price? We approached these knowledge gaps by
modeling the cost-effectiveness of sDNA in comparison
with WLE, chromoendoscopy, or no surveillance in a
hypothetical cohort of patients with US. Furthermore, we
sought to inform test design by 1-way sensitivity
analyses of test performance, interval, and cost. Lastly,
probabilistic sensitivity analyses (PSA) were performed
to assess the reliability of model outputs.Methods
This study was exempt from institutional review
board review.
Model Design
We adapted a previously published Markov model
with Monte Carlo simulations9 and imputed a clinical
course of UC, the incidence of colorectal neoplasia (cancer
plus dysplasia), and costs and beneﬁts of care with pa-
tients committed to 1 of 4 surveillance strategies: (1)
sDNA with diagnostic chromoendoscopy for sDNA-test
positives, (2) sDNA with diagnostic WLE for
sDNA-positives, (3) chromoendoscopy with targeted
biopsies only, or (4) WLE with random biopsies. The
model was originally created with TreeAge Pro 2009
(TreeAge, Williamstown, MA) and updated with TreeAge
2015. The Markov cycle length was 1 year. The simulation
sampled hypothetical patients, 8 years after population-
based age distribution of UC diagnosis, the recom-
mended duration to begin surveillance for dysplasia.17
Termination criteria were death or a patient age >90
years with 10 years of surveillance. Pancolitis and left-
sided disease were treated equally according to current
guidelines for surveillance.5 Health states included
chronic UC, chronic UC with dysplasia, status post-
colectomy, CRC, and death caused by either baseline
mortality or mortality related to colonoscopy, surgery, or
CRC (Figure 1). Base case values and ranges for transition
probabilities and health state utilities (Supplementary
Table 1) were obtained from a systematic literature
search as previously described.9 Several key adaptations
were included to address the speciﬁc aims of this study
(Table 1).
Table 1. Transition Probabilities and Healthcare Costs
Variable Base-case
Standard
deviationa
Monte Carlo
distribution typea
2.5th/97.5th
percentilea References
Stool DNA
Sensitivity LGD 0.41 0.018 Beta 0.38/0.45 14
Sensitivity HGD 0.69 0.072 Beta 0.56/0.85 14
Sensitivity CRC 0.92 0.35 Beta 0.84/0.98 14
Speciﬁcity 0.87 0.0036 Beta 0.86/0.87 14
Ulcerative colitis
% Adhering to surveillance 0.5 0.11 Beta 0.28/0.71 10
Age of UC diagnosis, y 17
10 0.075 — — — 17
30 0.354 — — — 17
50 0.279 — — — 17
70 0.238 — — — 17
90 0.054 — — — 17
Annual rate of CRC incidence
by UC duration, y
At 8th 0.0107 — Beta 0.00045–0.044 18
9–15 0.00135 — Beta 0.000032–0.0046 18
16–20 0.00205 — Beta 0.000044–0.0089 18
21 0.00207 Beta 0.000067–0.0075 18
Probability CRC stage at diagnosis
Surveillance
Dukes’ A/B 0.86 0.13 Beta 0.50/1.00 19
Dukes’ C 0.10 0.012 Beta 0.08/0.13 19
Dukes’ D 0.04 0.0065 Beta 0.03/0.06 19
No surveillance
Dukes’ A/B 0.47 0.071 Beta 0.33/0.60 19,31
Dukes’ C 0.38 0.044 Beta 0.29/0.49 19,31
Dukes’ D 0.15 0.024 Beta 0.11/0.20 19,31
Costs
Annual care UC $8485 $1061 Gamma $6326/$11,048 20
Stool DNA test $599 $75 Gamma $460/$744 CPT G0464
CE with biopsies $1221 $153 Gamma $932/$1589 CPT 88305
CPT 45380
WLE with biopsies $1405 $177 Gamma $978/$1714 CPT 88305
CPT 45380
Adverse event from colonoscopy $7075 $2653 Gamma $2636/$15,386 27
Colectomy cost þ 6-month
postoperative care
$62,453 $35,858 Gamma $17,004/$153,379 32,33
Routine care with IPAA (annual) $6058 $758 Gamma $4540/$7238 20
Cancer-related expenses, initial
Local $48,945 $6115 Gamma $37,994/$64,953 21,22
Regional $64,746 $8091 Gamma $52,209/$85,461 21,22
Distant $64,384 $8046 Gamma $49,446/$82,898 21,22
Cancer-related expenses, continuing
Local $3796 $475 Gamma $3126/$4799 21,22
Regional $7887 $986 Gamma $6078/$9916 21,22
Distant $26,570 $3321 Gamma $19,531/$33,248 21,22
Cancer-related expenses, terminal
Local $20,453 $2556 Gamma $16,126/$25,261 21,22
Regional $36,509 $4562 Gamma $27,348/$47,145 21,22
Distant $49,792 $6223 Gamma $39,566/$62,789 21,22
NOTE. Please see Supplementary Table 1 for additional model inputs and distributions.
CE, chromoendoscopy; CPT, current procedural terminology; HGD, high-grade dysplasia; IPAA, ileal pouch anal anastomosis.
aApply to probabilistic sensitivity analysis only.
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of Surveillance
Patients in the simulation cohort entered the model at
an age consistent with population-level measurements of
natural history.17 The probability of developing CRC,given no prior dysplasia, was modeled on population-
level estimates; patients entered the simulation at 8
years after diagnosis with a 1.07% incidence of CRC to
match cumulative incidence estimates of 2% at 15 years,
3% at 20 years, and 4% at 25 years.18 Surveillance co-
lonoscopy has been recently shown to reduce CRC
December 2016 Stool DNA Cost-Effective for UC CRC 1781incidence and all-cause mortality.3 To reﬂect this beneﬁt,
the model was designed to confer improved survival
from CRC if detected by surveillance in accordance with
previously published estimates.19
Stool DNA Test Performance in
Ulcerative Colitis
Base-case sDNA performance estimates were derived
from average-risk sDNA test performance,14 which are
more conservative than those available from the limited
literature in IBD patient populations.15,16 Also, each
surveillance strategy assumed base case compliance of
0.5, consistent with US surveillance adherence
estimates.10
Costs and Utilities
Care and procedure expenditures were based on
2014 Medicare reimbursement for speciﬁc procedures
(Table 1) or updated to 2014 United States dollars from
literature estimates (Supplementary Table 1)20–22 using
published medical Consumer Price Index inﬂation fac-
tors. Because sDNA cost for use in UC has not been
determined, and because Medicare has not issued a na-
tional coverage determination for sDNA testing in IBD,
the base cost was set at $599, the current price billed to
commercial insurance for the Cologuard multitarget
sDNA test for average-risk CRC screening (Exact Sci-
ences). All costs were estimated from the payer
perspective and did not include indirect patient expenses
(eg, travel, lost work time).
Transient utilities included UC ﬂare requiring colec-
tomy, immediate postoperative state, and adverse events
from either surgery or colonoscopy; these were modeled
with 1-month duration. In patients simulated to have
those events, yearly utilities were adjusted by a weighted
average of the transient utility and the underlying utility
attributed to chronic UC, post–ileal pouch anal anasto-
mosis state, or cancer (Dukes’ stage A/B vs C vs D). All
costs and utilities were discounted at a rate of 3% per
year.
Analyses
Base-case analysis was conducted by Markov
modeling with Monte Carlo microsimulation, which
sampled all costs, utilities, and probabilities to create
500,000 hypothetical patients and disease courses. The
primary outcome was the incremental cost-effectiveness
ratio (ICER; incremental cost/incremental difference in
quality-adjusted life-years [QALY]) for each surveillance
strategy at 2-year intervals compared with no surveil-
lance. A WTP threshold of $50,000 per QALY was used to
estimate cost-effectiveness.23
One-way sensitivity analyses evaluated the impact of
surveillance compliance, sDNA test cost, and sDNAsensitivity and speciﬁcity. A second set of sensitivity
analyses studied cost thresholds for a 1-year sDNA sur-
veillance program, compared with 2-year intervals for
chromoendoscopy and WLE.
To estimate the degree of uncertainty around the
model assumptions, PSA was then performed by simu-
lating 100 separate cohorts of 100,000 patients. Cost,
utility, and probability variable inputs were sampled by
the simulation software according to the distribution
type and margin of error around the base-case point
estimates (Table 1). Model uncertainty was also exam-
ined using cost-effectiveness acceptability curves, which
use a net monetary beneﬁt calculation (NMB) that com-
bines cost, effectiveness, and WTP into a single mea-
surement (NMB ¼ effectiveness  WTP – cost). The
strategy with the highest NMB is the most cost-effective
given the ﬁxed WTP parameter. The sampling variation
in the PSA was used to estimate the probability that a
surveillance strategy is cost-effective for a given WTP (ie,
the decision maker’s threshold ICER). Where the PSA
disagreed with the results of the base case analysis,
additional acceptability curves were generated to iden-
tify input variables that might potentially disrupt to the
expected outcome.Results
Base-Case Analysis
Relative to no surveillance, the primary cost-
effectiveness analysis demonstrated that ICERs for
annual, biennial, and every 3-year sDNA, chromoendo-
scopy, and WLE fell below the WTP threshold of $50,000
(Figure 2). Although all options were cost-effective, the
ICERs for sDNA-based surveillance were lower than and
not dominated by endoscopic-based options. Consistent
with prior results,9 chromoendoscopy modalities were
more cost-effective that WLE.
In the no surveillance strategy on 500,000 hypo-
thetical patients, the model generated 95,987 CRC cases,
resulting in 81,502 CRC-related deaths over the full
duration of the simulation. Biennial WLE reduced CRC
cases by 53,800 and associated fatalities by 42,274. To
prevent 1 additional CRC case, 9 patients would have to
participate in programmatic WLE surveillance. Biennial
chromoendoscopy prevented 52,539 cases and 42,104
hypothetical deaths with 10 surveillance program par-
ticipants needed to prevent 1 additional CRC. Although
less costly, sDNA with diagnostic chromoendoscopy, and
sDNA with diagnostic WLE, prevented 17,681 and
16,230 hypothetical CRC fatalities, respectively. To pre-
vent 1 additional CRC case, 18 and 19 patients would
have to participate in programmatic surveillance with
sDNA with diagnostic chromoendoscopy or diagnostic
WLE, respectively. Assuming 50% base-case compliance
with colonoscopy-based surveillance, and that non-
compliant patients used sDNA, 58,504 to 59,785 CRC
Figure 2. Incremental cost-effectiveness ratios for each surveillance strategy at (A) annual, (B) biennial, and (C) every 3-years
surveillance intervals compared with no surveillance, which cost $189,960 for 19.65 QALY. CE, chromoendoscopy.
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approach, only 5–8 patients would need to participate in
programmatic surveillance with to prevent 1 additional
CRC fatality.
Sensitivity Analyses on Individual Variables
All biennial surveillance modalities became more
expensive as patient compliance increased, but at all
levels of compliance at sDNA remained cost-effective.
Unless the speciﬁcity of sDNA fell below 0.65, sDNA
with diagnostic chromoendoscopy was preferred over
chromoendoscopy alone. Diagnostic sensitivity of sDNA
did not impact cost-effectiveness across a wide range of
performance (0.25–0.99) for any target lesion, which
included low-grade dysplasia (LGD), high-grade
dysplasia, or CRC. Test cost for sDNA was prohibitive
above $1135 at which point chromoendoscopy became
more cost-effective (Table 2). Similarly, in comparison of
sDNA with diagnostic WLE against WLE alone, sDNA
remained preferred unless the speciﬁcity of sDNA fell
below 0.66 or cost of sDNA exceeded $1109.If sDNA testing were to be performed annually, the
threshold cost for sDNA would decrease to $601 and
$675 to remain cost-effective when compared with
biennial interval chromoendoscopy or WLE, respectively.
Probabilistic Sensitivity Analysis
PSA supported the ﬁndings of the base-case analysis
(Figure 3, Supplementary Figure 1). Compared with no
surveillance, sDNA with diagnostic chromoendoscopy
was below the WTP threshold of $50,000 per QALY or
dominant in 71 of 100 hypothetical patient cohorts.
sDNA with diagnostic WLE or chromoendoscopy alone
were below the WTP of $50,000 per QALY or dominant
in 66 of the cohorts; WLE alone was below the WTP
threshold or dominant 55% of the time.
Base case analyses anticipated that sDNA-based op-
tions would show maximal NMB if payers were willing
to pay $18,000–$45,000 per QALY (Supplementary
Tables 2 and 3); however, acceptability curves for the
full set of input variables provided contradictory results
to the base case. To determine why this PSA was
Table 2.One-Way Sensitivity Analyses Assuming Biennial Testing Intervals
Comparison strategy Variable
Base-case
value
N simulated
individual patients
Range of sensitivity
analysis
Threshold
value
Chromoendoscopy Percent adhering to
sDNA screening
0.50 500,000 25–100 n/a
Cost of sDNA test $599 100,000 $600–$1500 $1135
Speciﬁcity of sDNA 0.866 100,000 0.25–0.99 0.65
Sensitivity of sDNA to CRC 0.923 100,000 0.25–0.99 n/a
Sensitivity of sDNA to HGD 0.692 100,000 0.25–0.99 n/a
Sensitivity of sDNA to LGD 0.409 100,000 0.25–0.99 n/a
White-light endoscopy Percent adhering to
sDNA screening
0.50 500,000 25–100 n/a
Cost of sDNA test $599 100,000 $600–$1800 $1109
Speciﬁcity of sDNA 0.866 100,000 0.25–0.99 0.66
Sensitivity of sDNA to CRC 0.923 100,000 0.25–0.99 n/a
Sensitivity of sDNA to HGD 0.692 100,000 0.25–0.99 n/a
Sensitivity of sDNA to LGD 0.409 100,000 0.25–0.99 n/a
HGD, high-grade dysplasia; n/a, not applicable.
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repeated with stratiﬁed sampling by each of the com-
bined utility, cost, and probability variables to identify
those that might be disruptive when sampled across the
entire Monte Carlo distribution. With this approach, the
output of all utility and cost variables remained consis-
tent with base-case expectations, whereas results based
on probability variables seemed contradictory
(Figure 4A–C). Sampling by individual probability vari-
ables generated curves that were each consistent with
base case, therefore interaction among probability vari-
ables was suspected. To further investigate this, all
probability inputs were sampled in clusters of 2–4 var-
iables at a time in combination with the CRC incidence
variable; however, each of these acceptability curves
matched base-case expectations (Figure 4D,
Supplementary Figure 2).Discussion
In this analysis of CRC surveillance strategies, sDNA
seems to be more cost-effective when used with either
diagnostic chromoendoscopy or diagnostic WLE than
chromoendoscopy alone or WLE alone. Although chro-
moendoscopy has recently been endorsed by the SCENIC
consensus statement,6 this modality is not yet widely
used, leaving many patients and providers to rely on
WLE. Endoscopy-based surveillance could become more
cost-effective if sDNA speciﬁcity falls below 0.65 in
comparison with chromoendoscopy surveillance alone or
below 0.66 in comparison with WLE. These speciﬁcity
thresholds are well below currently published estimates
of sDNA performance in either patients with IBD15,16 or
in the average risk population.14 The relative cost-
effectiveness of sDNA was maintained across a wide
spectrum of patient compliance, test sensitivity, and test
costs. Even annual sDNA testing was cost-effective incomparison with either annual or biennial endoscopy-
based options.
Regardless of test strategy, surveillance for dysplasia
and CRC in patients with US seems cost-effective. These
ﬁndings shed new light on a long-standing clinical un-
certainty because previous economic analyses of endo-
scopic surveillance for CRC in patients with US have
yielded mixed results. Provanzale et al24 performed a
cost-effectiveness analysis of WLE colonoscopy in UC at
1- to 5-year intervals in comparison with no surveillance.
Although surveillance at intervals shorter than 5 years
seemed to exceed WTP, the ICERs for all intervals were
comparable with other commonly performed screening
tests, such as cervical cancer screening.24 Subsequent
threshold analyses and critical reviews on surveillance
cost-effectiveness have highlighted that test cost, CRC
incidence, mortality reduction from surveillance, and
quality of life after proctocolectomy are critical factors,
whereas diagnostic accuracy of colonoscopy did not
greatly impact results.9,25–27 Consistent with these model
outputs, our present analysis did not reveal signiﬁcant
threshold effects when varying the sensitivity of sDNA,
although thresholds for speciﬁcity and cost were
observed.
The present results also update a recent economic
analysis of chromoendoscopy and WLE strategies that
found dominance by chromoendoscopy but at costs
exceeding WTP of $100,000.9 The substantial relative
QALY gains we observed were most likely caused by the
incorporation of recent data showing that WLE lowers
CRC incidence and improves mortality.3 Surveillance of
patients with US with WLE has only been shown to
reduce CRC incidence in 1 observational study; 2 others
showed earlier stage CRC diagnosis with corresponding
mortality beneﬁt.19,28 There has been further concern
that chromoendoscopy may overestimate risk of subse-
quent advanced neoplasia in patients with LGD by
ﬁnding more lesions with uncertain natural history.13,29
Figure 3. (A) ICER scatter
plot and 95% conﬁdence
interval ellipse in relation-
ship to $50,000 WTP
threshold for stool DNA
with diagnostic chro-
moendoscopy in reference
to no surveillance. Quad-
rants I–IV are deﬁned by
cost and effectiveness
axes and components 1–6
deﬁne where stool DNA is
recommended or not in
relationship to WTP. (B)
Interpretation key shows
that stool DNA with diag-
nostic chromoendoscopy
was the recommended
surveillance strategy in
most (71%) cohorts in
which the full range of
model parameters was
sampled.
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cohort in the United Kingdom showed that the rate of
progression from LGD to CRC was similar across each of
4 decades suggesting that the more recent introduction
of chromoendoscopy has not changed the apparent risk
attributable to LGD.28 The present model also relied on
encouraging but preliminary available data on sDNA
performance in IBD.15,16 Because small sample size and
single-center experience should prompt a cautious
approach, we opted to use more conservative sDNA
performance inputs from a large clinical trial of average-
risk, asymptomatic patients in the general population,14
and used 1-way and PSA to evaluate sDNA
cost-effectiveness across wide hypothesized ranges of
test performance. Results from a large multicentercase-control study on sDNA performance in patients with
IBD are eagerly anticipated (ClinicalTrials.gov identiﬁer
NCT01819766).
There are several potential limitations to this study. The
acceptability curve generated from the full set of variables
seemed contrary to the base-case results. Stratifying by
inputs of utilities, costs, and probabilities seemed to isolate
probability variables; however, despite sampling proba-
bility variables individually and in groups of 2–4 at a time,
we were unable to identify any potentially disruptive in-
puts. Therefore, we remain conﬁdent in the base-case
ﬁndings. There is also the potential to underestimate
costs. Inputs for costs of endoscopic procedures, compli-
cations, surgery, and cancer care were modeled from the
Medicare perspective, and may be lower than
Figure 4. Acceptability curves for the each of the major input variable categories (A) utilities, (B) costs, and (C) probabilities.
Probabilities were further examined in smaller clusters of variables at a time (D) that all met base-case expectations.
December 2016 Stool DNA Cost-Effective for UC CRC 1785reimbursement rates from commercial insurance carriers.
Also, themodel did not include any indirect costs. Although
there is precedent for their exclusion because of the difﬁ-
culty of accurate measurement,24,25,27 this may underesti-
mate the total burden to society.We are encouraged that surveillance for CRC in pa-
tients with US seems cost-effective, because the ICER
estimates of all options fell below a WTP of $50,000.
Based on our modeling, sDNA was most cost-effective
relative to no surveillance. The user-friendly features of
1786 Kisiel et al Clinical Gastroenterology and Hepatology Vol. 14, No. 12sDNA may improve patient compliance,30 and its addi-
tion as an option in the surveillance arsenal may enhance
overall effectiveness.
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Supplementary Figure 1. Probabilistic sensitivity analysis summary. (A) Biennial stool DNA testing with diagnostic white-light
colonoscopy versus no surveillance (natural history). (B) Biennial chromoendoscopy versus no surveillance (natural history). (C)
Biennial white-light colonoscopy versus no surveillance (natural history).
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Supplementary Figure 1. (continued).
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Supplementary Figure 1. (continued).
1787.e3 Kisiel et al Clinical Gastroenterology and Hepatology Vol. 14, No. 12
Supplementary Figure 2. Sampling of CRC incidence rate with additional clusters of 2 or 4 probability-based variables.
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Supplementary Table 1. Additional Transition Probabilities, Utilities, and Model Variables
Variable Base-case Range
Monte Carlo distribution
(base-case, 95% CI) References
Ulcerative colitis
Annual rate of UC ﬂare requiring colectomy 0.0023 0.0016–0.0075 Beta (0.0023; 0.0015) 1,2
Probability of death due to other causes in UC 0.0013 0.0001–0.003 Beta (0.0013; SD 0.0007) 3
Colonoscopy test characteristic
WLE sensitivity for dysplasia 0.695 0.00–1.00 Beta (0.695; SD 0.100) 4–7
WLE speciﬁcity for dysplasia 0.9 0.00–1.00 Beta (0.90; SD 0.15) 4,7,8
WLE or chromoendoscopy sensitivity for CRC 0.9 0.80–1.00 Beta (0.9; SD 0.05) 4,6,9
WLE or chromoendoscopy speciﬁcity for CRC 0.999 0.90–1.00 Beta (0.999; SD 0.025) 1,4
Chromoendoscopy sensitivity for dysplasia in UC 0.833 0.36–1.00 Beta (0.833; SD 0.159) 7,10
Chromoendoscopy speciﬁcity for dysplasia in UC 0.913 0.44–1.00 Beta (0.913; SD 0.141) 8,10
Dysplasia
Probability of LGD if dysplasia on
surveillance colonoscopy
0.75 0.61–0.80 Beta (0.75; SD 0.048) 7,11
Probability of HGD if dysplasia on
surveillance colonoscopy
0.25 0.20–0.38 Beta (0.25; SD 0.045) 7,11
Proportion proceeding to colectomy if LGD 0.60 0–1.00 Beta (0.60; SD 0.25) 12
Probability of synchronous CRC if LGD 0.19 0.04–0.46 Beta (0.19; SD 0.105) 13,14
Probability of developing CRC given LGD 0.14 0.090–0.314 Beta (0.140; SD 0.056) 14
Probability of synchronous CRC if HGD 0.53 0.42–0.67 Beta (0.53; SD 0.06) 13,15
Probability of dysplasia in chronic UC 0.0036 0.0008–0.015 Beta (0.0036; SD 0.004) 16
Cancer progression (annual transition proportion)
From local CRC to regional CRC 0.20 0.10–0.30 Beta (0.20; SD 0.05) 17
From regional CRC to distant CRC 0.40 0.20–0.60 Beta (0.40; SD 0.10) 17
Cancer mortality
Local cancer (Dukes’ A/B, stage 1–2) 0.0211 0.0158–0.0263 Beta (0.0211; SD 0.0026) 18
Regional cancer (Dukes’ C, stage 3) 0.0699 0.0524–0.0874 Beta (0.0699; SD 0.0088) 18
Distant cancer (Dukes’ D, stage 4) 0.3467 0.2600–0.4334 Beta (0.3467; SD 0.0434) 18
Adverse events
Mortality from emergent colectomy 0.024 0.018–0.16 Beta (0.024; SD 0.036) 19
Mortality from elective colectomy 0.006 0.0035–0.066 Beta (0.006; SD 0.016) 1,19
Mortality from colectomy for CRC 0.042 0.039–0.057 Beta (0.042; SD 0.005) 20
Morbidity from emergent colectomy 0.421 0.316–0.526 Beta (0.421; SD 0.053) 19
Morbidity from elective colectomy 0.346 0.260–0.433 Beta (0.346; SD 0.043) 19
Morbidity from colectomy for CRC 0.384 0.278–0.405 Beta (0.384; SD 0.032) 21
Mortality from surveillance colonoscopy 0.00007 0.00006–0.0003 Beta (0.00007; SD 0.00006) 21
Morbid adverse event from surveillance
Colonoscopy
0.005 0.001–0.009 Beta (0.005; SD 0.002) 21
Perforation from surveillance colonoscopy 0.0001 0.00003–0.003 Beta (0.0001; SD 0.0007) 21
Utilities
Chronic UC, with or without dysplasia 0.94 0.85–1.0 Triangular (0.94, 0.85, 1.0) 22,23
Post-IPAA 0.9 0.84–0.94 Triangular (0.90, 0.84, 0.94) 21
Local cancer (Dukes’ A/B, stage 1–2) 0.74 0.69–0.78 Triangular (0.74, 0.69, 0.78) 24
Regional cancer (Dukes’ C, stage 3) 0.59 0.54–0.69 Triangular (0.59, 0.54, 0.69) 24
Distant cancer (Dukes’ D, stage 4) 0.25 0.20–0.31 Triangular (0.25, 0.20, 0.31) 24
Severe UC ﬂare resulting in colectomy 0.42 (1 mo) 0.10–0.70 Triangular (0.42, 0.10, 0.70) 21,23
Surgery (IPAA or other type of colectomy) 0.61 (1 mo) 0.32–0.84 Triangular (0.61, 0.32, 0.84) 23
Colonoscopy adverse events 0.031 (1 mo) 0.001–0.125 Triangular (0.031, 0.001, 0.125) 1
Postoperative adverse events 0.55 (1 mo) 0.30–0.70 Triangular (0.55, 0.30, 0.70) 23
Other variables
Discount rate 3% 25,26
Cycle length, y 1 0–10
Willingness to pay threshold $50,000/QALY 27
CI, Conﬁdence interval; SD, standard deviation; HGD, high-grade dysplasia; IPAA, ileal pouch anal anastomosis.
Adapted from Konijeti GG, Shrime MG, Ananthakrishnan AN, et al. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients
with ulcerative colitis. Gastrointest Endosc 2014;79:455–465; with permission.
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Supplementary Table 2. Conversion of Incremental Cost-effectiveness Ratio (ICER) to Net Monetary Beneﬁt (NMB) for No
Surveillance, Diagnostic Chromoendoscopy and Surveillance Chromoendoscopy
Relative
to baseline
analysis Strategy name Cost EFF
INCRCOST
vs baseline
INCREFF
vs baseline
ICER
vs baseline
No surveillance 189960.26 19.65 0 0 0
Biennial sDNA testing with
diagnostic chromoendoscopy
194812.43 19.95 4852.173 0.297 16362
Chromoendoscopy every 2 y 200260.79 20.08 10300.532 0.432 23830
Incremental
analysis Strategy name Cost EFF
INCRCOST
vs baseline
INCREFF
vs baseline
ICER
vs baseline
No surveillance 189960.26 19.65 0 0 0
Biennial sDNA testing with
diagnostic chromoendoscopy
194812.43 19.95 4852.1727 0.2965 16362
Chromoendoscopy every 2 y 200260.79 20.08 5448.3589 0.1357 40151
NMB Strategy name
NMB at
WTP 0
NMB
at WTP
5000
NMB
at WTP
10000
NMB
at WTP
15000
NMB
at
16362
NMB
at
25000
NMB
at
30000
NMB
at
35000
NMB
at
40000
NMB
at
40151
NMB
at
45000
NMB
at
50000
No surveillance -189960.26 -91707 6545 104798 131562 301304 399556 497809 596062 599029 694315 792568
Biennial sDNA
testing with
diagnostic
chromoendoscopy
-194812.43 -95077 4659 104394 131562 303865 403601 503336 603072 606084 702807 802543
Chromoendoscopy
every 2 y
-200260.79 -99847 567 100981 128334 301809 402223 502637 603051 606084 703465 803879
NOTE. Highest NMB ¼ optimal strategy at WTP.
EFF, effectiveness; INCRCOST, incremental cost; INCREFF, incremental effectiveness.
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Supplementary Table 3. Conversion of Incremental Cost-effectiveness Ratio (ICER) to Net Monetary Beneﬁt (NMB) for No
Surveillance, Diagnostic White-light Endoscopy and Surveillance White-light Endoscopy
Relative
to baseline
analysis Strategy name Cost EFF
INCRCOST
vs baseline
INCREFF
vs baseline
ICER
vs baseline
No surveillance 189960.26 19.65 0 0 0
Biennial sDNA testing with
diagnostic white-light endoscopy
194913.88 19.92 4953.626 0.266 18643
White-light endoscopy every 2 y 201112.19 20.05 11151.933 0.400 27907
Incremental
analysis Strategy name Cost EFF INCRCOST INCREFF ICER
No surveillance 189960.258 19.6505576 0 0 0
Biennial sDNA testing with
diagnostic white-light endoscopy
194913.884 19.9162713 4953.62627 0.26571368 18643
White-light endoscopy every 2 y 201112.191 20.0501625 6198.30722 0.13389119 46294
NMB Strategy name
NMB at
WTP 0
NMB
at WTP
5000
NMB
at WTP
10000
NMB
at WTP
15000
NMB at
18642.73
NMB at
25000
NMB at
30000
NMB at
40000
NMB at
46294
NMB at
50000
No surveillance -189960.26 -91707.47 6545.32 104798.11 176379.78 301303.68 399556.47 596062.05 719742.66 792567.62
Biennial sDNA
testing with
diagnostic
white-light
endoscopy
-194913.88 -95332.53 4248.83 103830.19 176379.78 302992.90 402574.26 601736.97 727089.98 800899.68
White-light
endoscopy
every 2 y
-201112.19 -100861.38 -610.57 99640.25 172677.57 300141.87 400392.68 600894.31 727090.03 801395.93
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